Short Interest in OSR Holdings, Inc. (NASDAQ:OSRH) Increases By 461.9%

OSR Holdings, Inc. (NASDAQ:OSRH) was the recipient of a large increase in short interest in April. As of April 30th, there was short interest totaling 1,282,018 shares, an increase of 461.9% from the April 15th total of 228,151 shares. Based on an average daily volume of 28,596,577 shares, the short-interest ratio is presently 0.0 days. Approximately 9.8% of the company’s stock are short sold.

OSR Trading Down 2.7%

NASDAQ:OSRH traded down $0.02 on Thursday, reaching $0.60. The stock had a trading volume of 1,118,154 shares, compared to its average volume of 5,024,482. The company has a 50-day moving average of $0.54 and a 200 day moving average of $0.58. The stock has a market cap of $21.06 million, a P/E ratio of -0.47 and a beta of 0.86. OSR has a 12-month low of $0.38 and a 12-month high of $1.79.

OSR (NASDAQ:OSRH) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $0.48 million during the quarter. OSR had a negative net margin of 619.82% and a negative return on equity of 13.53%.

Hedge Funds Weigh In On OSR

A hedge fund recently bought a new stake in OSR stock. Susquehanna International Group LLP acquired a new stake in OSR Holdings, Inc. (NASDAQ:OSRH) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned about 0.37% of OSR at the end of the most recent reporting period. 55.30% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on OSRH. Weiss Ratings reiterated a “sell (e+)” rating on shares of OSR in a report on Friday, March 27th. Wall Street Zen upgraded OSR from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.